Search

Displaying results 721 - 730 of 3599 in total
  1. Target

    Interleukin-17 receptor A

    go.drugbank.com/bio_entities/BE0018249
    TargetHumans

    Receptor for IL17A (PubMed:17911633, PubMed:9367539). Receptor for IL17F (PubMed:17911633, PubMed:19838198). Binds to IL17A with higher affinity than to IL17F (PubMed:17911633). … Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848)

    Polypeptides: Interleukin-17 receptor ASynonyms: IL-17 receptor A
  2. Target

    Interleukin-17 receptor B

    go.drugbank.com/bio_entities/BE0020027
    TargetHumans

    Receptor for the pro-inflammatory cytokines IL17B and IL17E. May play a role in controlling the growth and/or differentiation of hematopoietic cells

    Polypeptides: Interleukin-17 receptor BSynonyms: IL-17 receptor B, IL-17B receptor
  3. Target

    Insulin receptor substrate 2

    go.drugbank.com/bio_entities/BE0021286
    TargetHumans

    Signaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R (PubMed:25879670 … Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of

    Polypeptides: Insulin receptor substrate 2
  4. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  5. Drug

    Insulin glargine

    go.drugbank.com/drugs/DB00047
    ApprovedInvestigational

    The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  6. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus.

  7. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    Dosulepin (INN, BAN) formerly known as dothiepin (USAN), is a tricyclic antidepressant with anxiolytic properties that is used in several European and South Asian countries, as well as Australia, South

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  8. Drug

    Daprodustat

    go.drugbank.com/drugs/DB11682
    ApprovedInvestigational

    Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK. Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent in...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  9. Drug

    Polysorbate 80

    go.drugbank.com/drugs/DB11063
    ApprovedInvestigational

    Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it acts as an emulsifier, a solubilizer...

    Mixtures: Refresh Digital PFCategories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    [A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.[A1492] … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Enzyme Inhibitors